99 related articles for article (PubMed ID: 15050748)
1. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line.
Tarumoto T; Nagai T; Ohmine K; Miyoshi T; Nakamura M; Kondo T; Mitsugi K; Nakano S; Muroi K; Komatsu N; Ozawa K
Exp Hematol; 2004 Apr; 32(4):375-81. PubMed ID: 15050748
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity.
Arlt A; Sebens S; Krebs S; Geismann C; Grossmann M; Kruse ML; Schreiber S; Schäfer H
Oncogene; 2013 Oct; 32(40):4825-35. PubMed ID: 23108405
[TBL] [Abstract][Full Text] [Related]
3. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway.
Gao AM; Ke ZP; Shi F; Sun GC; Chen H
Chem Biol Interact; 2013 Oct; 206(1):100-8. PubMed ID: 23994249
[TBL] [Abstract][Full Text] [Related]
4. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
Singh A; Venkannagari S; Oh KH; Zhang YQ; Rohde JM; Liu L; Nimmagadda S; Sudini K; Brimacombe KR; Gajghate S; Ma J; Wang A; Xu X; Shahane SA; Xia M; Woo J; Mensah GA; Wang Z; Ferrer M; Gabrielson E; Li Z; Rastinejad F; Shen M; Boxer MB; Biswal S
ACS Chem Biol; 2016 Nov; 11(11):3214-3225. PubMed ID: 27552339
[TBL] [Abstract][Full Text] [Related]
5. A Small Molecule Inhibits Deregulated NRF2 Transcriptional Activity in Cancer.
Bollong MJ; Yun H; Sherwood L; Woods AK; Lairson LL; Schultz PG
ACS Chem Biol; 2015 Oct; 10(10):2193-8. PubMed ID: 26270491
[TBL] [Abstract][Full Text] [Related]
6. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
Wang XJ; Hayes JD; Henderson CJ; Wolf CR
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19589-94. PubMed ID: 18048326
[TBL] [Abstract][Full Text] [Related]
7. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
8. Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer.
Broekgaarden M; Anbil S; Bulin AL; Obaid G; Mai Z; Baglo Y; Rizvi I; Hasan T
Biomaterials; 2019 Nov; 222():119421. PubMed ID: 31494503
[TBL] [Abstract][Full Text] [Related]
9. An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer.
Wu L; Zhou B; Oshiro-Rapley N; Li M; Paulo JA; Webster CM; Mou F; Kacergis MC; Talkowski ME; Carr CE; Gygi SP; Zheng B; Soukas AA
Cell; 2016 Dec; 167(7):1705-1718.e13. PubMed ID: 27984722
[TBL] [Abstract][Full Text] [Related]
10. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
11. Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells.
Peng H; Wang H; Xue P; Hou Y; Dong J; Zhou T; Qu W; Peng S; Li J; Carmichael PL; Nelson B; Clewell R; Zhang Q; Andersen ME; Pi J
Toxicol Appl Pharmacol; 2016 Feb; 292():1-7. PubMed ID: 26708503
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid prevents Nrf2 translocation by inhibiting ERK1 phosphorylation and induces oxidative stress and apoptosis.
Verma AK; Yadav A; Dewangan J; Singh SV; Mishra M; Singh PK; Rath SK
Redox Biol; 2015 Dec; 6():80-92. PubMed ID: 26202867
[TBL] [Abstract][Full Text] [Related]
13. 3',4',5',5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway.
Hou X; Bai X; Gou X; Zeng H; Xia C; Zhuang W; Chen X; Zhao Z; Huang M; Jin J
Mol Cells; 2015 May; 38(5):396-401. PubMed ID: 25843086
[TBL] [Abstract][Full Text] [Related]
14. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.
Olayanju A; Copple IM; Bryan HK; Edge GT; Sison RL; Wong MW; Lai ZQ; Lin ZX; Dunn K; Sanderson CM; Alghanem AF; Cross MJ; Ellis EC; Ingelman-Sundberg M; Malik HZ; Kitteringham NR; Goldring CE; Park BK
Free Radic Biol Med; 2015 Jan; 78():202-12. PubMed ID: 25445704
[TBL] [Abstract][Full Text] [Related]
15. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway.
Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q
Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
Valenzuela M; Glorieux C; Stockis J; Sid B; Sandoval JM; Felipe KB; Kviecinski MR; Verrax J; Buc Calderon P
Br J Cancer; 2014 Aug; 111(5):874-82. PubMed ID: 25003661
[TBL] [Abstract][Full Text] [Related]
17. NF-κB and Nrf2 signaling pathways contribute to wogonin-mediated inhibition of inflammation-associated colorectal carcinogenesis.
Yao J; Zhao L; Zhao Q; Zhao Y; Sun Y; Zhang Y; Miao H; You QD; Hu R; Guo QL
Cell Death Dis; 2014 Jun; 5(6):e1283. PubMed ID: 24901054
[TBL] [Abstract][Full Text] [Related]
18. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
19. A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity.
Limonciel A; Jennings P
Toxins (Basel); 2014 Jan; 6(1):371-9. PubMed ID: 24448208
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine.
Duong HQ; Yi YW; Kang HJ; Hong YB; Tang W; Wang A; Seong YS; Bae I
Int J Oncol; 2014 Mar; 44(3):959-69. PubMed ID: 24366069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
